Library / Peptides / Hormone Optimization / Mod GRF 1-29

Emerging evidence · Grade B

Mod GRF 1-29

CJC-1295 Without DAC (Modified GRF 1-29)

Evidence

Emerging

Route

Subcutaneous injection

Frequency

1-3x daily (often before bed, combined with GHRP)

Mechanism.

CJC-1295 without DAC, also known as Modified GRF (1-29) or tesamorelin-related analog, is a synthetic analog of growth hormone-releasing hormone (GHRH) with four amino acid substitutions that increase its half-life to approximately 30 minutes (vs. minutes for native GHRH). It stimulates pulsatile growth hormone release from the pituitary and is commonly used in combination with GHRP peptides (like ipamorelin) in anti-aging and performance medicine.

Think of your pituitary gland as a sprinkler system. Modified GRF 1-29 is like pressing the 'on' button to release growth hormone in its natural pulsatile pattern, rather than leaving the hose running constantly like injecting GH directly would.

Mechanism · technical

Modified GRF 1-29 binds to the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells, activating adenylyl cyclase via Gs-protein signaling. This raises intracellular cAMP, which triggers pulsatile GH release. The four amino acid substitutions (Ala2, Gln8, Ala15, Leu27) protect it from enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV), extending its bioactivity compared to native GHRH.

Part 02 · Dosing & administration

How it's taken.

Values below describe how Mod GRF 1-29 has been administered in published trials and labeling. Provided for educational purposes only — this is not medical advice and not instructions for self-administration. Consult your healthcare provider before making any health decision.

Standard dose

100-300 mcg

Subcutaneous injection · 1-3x daily (often before bed, combined with GHRP)

Duration

8-12 weeks typical cycle

Modified GRF 1-29. Short half-life (~30 min) unlike CJC-1295 with DAC. Produces pulsatile GH release (more physiologic). Almost always combined with a GHRP (e.g., ipamorelin). Not FDA-approved.

Need help with reconstitution?

Use the free peptide calculator for dilution, unit conversion, and injection volume.

Open calculator

Part 03 · Safety

Side effects, rare serious events, who shouldn't.

Reported side effects

Common side effects include flushing, headache, dizziness, and injection site reactions. May cause transient water retention and paresthesias. Potential for elevated IGF-1 with long-term use, raising theoretical concerns about cancer risk with sustained supraphysiologic GH stimulation.

Absolute · do not use

Active malignancy or history of cancer

Pituitary tumor or hypothalamic disorders

Diabetic retinopathy

Pregnancy or breastfeeding

Children under 18 (unless for diagnosed GH deficiency under specialist care)

Known hypersensitivity to CJC-1295 or any component

Interactions

Insulin

GH secretagogues can increase insulin resistance; may require insulin dose adjustment

Major

Oral hypoglycemics

GH elevation may counteract glucose-lowering effects; monitor blood glucose

Moderate

Corticosteroids

Chronic corticosteroid use blunts GH release and may reduce efficacy

Moderate

Thyroid hormone replacement

GH can increase T4 to T3 conversion; thyroid levels may need reassessment

Moderate

Labs to monitor

IGF-1

Baseline, 4 weeks, then every 3 months

Monitor growth hormone axis stimulation

Fasting Glucose & Insulin

Baseline and monthly

GH can impair insulin sensitivity

CMP (Comprehensive Metabolic Panel)

Baseline and every 3 months

Liver and kidney function

HbA1c

Baseline and every 3 months

Track glycemic effects over time

Part 04 · Research log

Every study we cite.

Each study with its published finding and a plain-language note on limitations or funding.

2006

Modified GRF 1-29 pharmacokinetics

Modified GRF 1-29 maintained GHRH activity with improved protease resistance compared to native GHRH

Pharmacokinetic characterization study

2005

GHRH + GHRP synergy in GH release

Combined GHRH and GHRP administration produces synergistic GH release far exceeding either alone

Well-established pharmacologic principle

PMID 15705207 ↗

Part 05 · Cost & access

Where you can get it.

Regulatory status

Not FDA-approved. Available through compounding pharmacies with a prescription in the US, though the FDA has placed some GH secretagogues on the Category 2 bulk drug substances list, restricting compounding. Regulatory status has been evolving since 2023.

The Peptide Column takes no affiliate commission from any source.

Part 06 · Your appointment

Questions to bring.

What are my current IGF-1 and GH levels, and would GH stimulation be appropriate?

How does Modified GRF 1-29 differ from direct GH replacement in terms of safety?

Should this be combined with a GHRP like ipamorelin, and what are the pros and cons?

What monitoring (IGF-1, glucose, cancer screening) should I have while using GH secretagogues?